Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baxdrostat - AstraZeneca

Next Previous
Drug Profile

Baxdrostat - AstraZeneca

Alternative Names: BAXFENDY; CIN-107

Latest Information Update: 26 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer AstraZeneca
  • Class Amides; Antihypertensives; Antisecretories; Heart failure therapies; Isoquinolines; Small molecules; Urologics
  • Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hypertension
  • Phase III Heart failure; Hyperaldosteronism; Renal failure
  • Discontinued Spinal cord disorders

Most Recent Events

  • 26 Jun 2026 AstraZeneca plans a phase III BaxREMODEL CardioLink-18 trial for Hypertension and Left ventricular hypertrophy in Canada (PO, Tablet) in June 2026 (NCT07655362)
  • 20 May 2026 Discontinued - Phase-I for Spinal cord disorders in USA (unspecified route) (AstraZeneca pipleline; May 2026)
  • 20 May 2026 Baxdrostat - CinCor Pharma receives Fast Track designation for Hypertension [PO,Tablet] (Treatment-experienced) in Turkey

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top